Drugs / Mycophenolate mofetil (MMF)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT00972101 Background | Sep 2009 → Sep 2011 | disease related to hematopoietic stem cell transplant, leukemia, lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03734601 Background | Nov 2018 → Dec 2019 | Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +2 | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00185614 Background | Aug 2000 → Apr 2009 | plasma cell myeloma | Wen-Kai Weng | Completed | No outcome recorded |
| Phase 3 | NCT06821542 Background | Jun 2025 → May 2028 expected | chronic graft versus host disease | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01843348 Comparator | Dec 2012 → Mar 2016 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00568633 Background | Aug 2007 → Dec 2015 | acute myeloid leukemia | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02936505 Background | Oct 2016 → Oct 2025 overdue | — | Vastra Gotaland Region | Active not recruiting | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mycophenolate Mofetil (MMF) | “• Mycophenolate mofetil (MMF)” NCT06821542 ↗ |
| Route | Oral | “by mouth” NCT00185614 ↗ |